Recursion Pharmaceuticals (RXRX) EBIAT (2020 - 2025)
Historic EBIAT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$162.3 million.
- Recursion Pharmaceuticals' EBIAT fell 6929.22% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 8942.19%. This contributed to the annual value of -$463.7 million for FY2024, which is 4133.16% down from last year.
- Per Recursion Pharmaceuticals' latest filing, its EBIAT stood at -$162.3 million for Q3 2025, which was down 6929.22% from -$171.9 million recorded in Q2 2025.
- Recursion Pharmaceuticals' 5-year EBIAT high stood at -$30.7 million for Q1 2021, and its period low was -$202.5 million during Q1 2025.
- In the last 5 years, Recursion Pharmaceuticals' EBIAT had a median value of -$76.7 million in 2023 and averaged -$92.3 million.
- As far as peak fluctuations go, Recursion Pharmaceuticals' EBIAT plummeted by 15201.04% in 2021, and later skyrocketed by 1145.95% in 2022.
- Quarter analysis of 5 years shows Recursion Pharmaceuticals' EBIAT stood at -$64.9 million in 2021, then grew by 11.46% to -$57.5 million in 2022, then plummeted by 61.75% to -$93.0 million in 2023, then crashed by 92.38% to -$178.9 million in 2024, then increased by 9.31% to -$162.3 million in 2025.
- Its EBIAT stands at -$162.3 million for Q3 2025, versus -$171.9 million for Q2 2025 and -$202.5 million for Q1 2025.